False profits and silent partners in health care

Nutrition and Health

Volumn 20, Issue 2, 2009, Pages 79-89

  Lands, Bill ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDIBLE OIL;

ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; DIET; ECONOMICS; HEALTH CARE DELIVERY; HEALTH INSURANCE; HEALTH PROMOTION; HUMAN; METHODOLOGY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

CARDIOVASCULAR DISEASES; DELIVERY OF HEALTH CARE; DIET; DIETARY FATS, UNSATURATED; HEALTH PROMOTION; HUMANS; INSURANCE, HEALTH; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 70350116332     PISSN: 02601060     EISSN: None     Source Type: Journal    
DOI: 10.1177/026010600902000201     Document Type: Article

References (28)

1. http://www.cdc.gov/DHDSP/about-program.htm
2. Weinstein, M. C., Coxson, P. G., Williams, L. W., Pass, T. M., Stason, W. B. and Goldman L. (1987). Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health, 77 (11), 1417-1426.
3. http://www.businessinsurance.com/cgi-bin/printStory.pl?article-id=23602
4. https://www.hmrc.kines.umich.edu/hra/toc.cgi
5. Lands, W. E. M. (2003). Primary prevention in cardiovascular disease: moving out of the shadows of the truth about death. Nutr. Metab. Cardiovasc. Dis., 13, 154-164.
6. De Gruttola, V. G., Clax, P., DeMets, D. L., Downing, G. J., Ellenberg, S. S., Friedman, L., Gail, M. H., Prentice, R., Wittes, J. and Zeger, S. L. (2001). Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials: Summary of a National Institutes of Health Workshop. Controlled Clinical Trials, 22, 485-502.
7. Lands, B. (2008). A critique of paradoxes in current advice on dietary lipids. Prog Lipid Res. Mar., 47 (2), 77-106.
8. Steinberg, D. (2006). Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy. Part IV: The 1984 coronary primary prevention trial ends it - almqst. J Lipid Res., 47 (1), 1-14.
9. Carey, J. (2008). Do Cholesterol drugs do any good? Business Week Jan. 17, http://www.businessweek.com/magazine/content/08-04/b4068052092994.htm.
10. Studer, M., Briel, M, Leimenstoll, B., Glass, T. R. and Bucher, H. C. (2005). Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med., 165 (7), 725-730.
11. Oh, R. C., Beresford, S. A. A. and Lafferty, W. E. (2006). The fish in secondary prevention of heart disease (FISH) survey - Primary care physicians and omega 3 fatty acid prescribing behaviors. J. Am. Bd. Family Med., 19 (5), 459-467.
12. Carey, J. (2008). A Weak Prognosis for Vytorin and Zetia. Business Week March 31. http://www.businessweek.com/print/bwdaily/dnflash/content/mar2008/ db20080331-704360.htm.
13. Carey, J. (2008). Heart Disease: Not about cholesterol? Business Week Apr. 15. http://www.businessweek.com/print/bwdaily/dnflasn/content/apr2008/ db20080414-050826.htm.
14. Couzin, J. (2008). Cholesterol veers off script. Science, 322, 220-223.
15. Hoogwerf, B. J. (2008). Action to Control Cardiovascular Risk in; Diabetes Study Group. Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD. Cleve Clin J Med., 75 (10), 729-737.
16. Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M. Jr, Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., Nordestgaard, B. G., Shepherd, J., Willerson, J. T. and Glynn, R. J. (2008). JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med., Nov. 20, 359 (21), 2195-207.
17. Loeppke, R., Taitel, M., Richling, D., Parry, T., Kessler, R. C., Hymel, P. and Konicki, D. (2007). Health and productivity as a business strategy. J Occup Environ Med., Jul., 49 (7), 712-721.
18. Lands, W. E. M. (2003). Diets could prevent many diseases. Lipids, 18, 317-321.
19. Lands, W. E., Libelt, B., Morris, A., Kramer, N. C., Prewitt, T. E., Bowen, P., Schmeisser, D., Davidson, M. H. and Burns, J. H. (1992). Maintenance of lower proportions of (n-6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n-3) fatty acids. Biochim Biophys Acta., Dec. 10, 1180 (2), 147-162.
20. Hibbeln, J. R., Nieminen, L. R., Blasbalg, T. L., Riggs, J. A. and Lands, W. E. (2006). Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr, 83 (Suppl. 6), 1483S-1493S.
21. Hibbeln, J. R., Davis, J. M., Steer, C., Emmett, P., Rogers, I., Williams, C. and Golding, J. (2007). Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study) : an observational cohort study. Lancet, Feb. 17, 369 (9561), 578-585. (Pubitemid 46241443)
22. Freeman, M. P., Hibbeln, J. R., Wisner, K. L., Davis, J. M., Mischoulon, D., Peet, M., Keck, P. E. Jr, Marangell, L. B., Richardson, A. J., Lake, J. and Stoll, A. L. (2006). Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry, Dec, 67 (12), 1954-1967.
23. Ralston, N. V., Ralston, C. R., Blackwell, J. L. 3rd and Raymond, L. J. (2008). Dietary and tissue selenium in relation to methylmercury toxicity. Neurotoxicology, 29, 802-811.
24. Healy, B. (2008). From Fish Oil to Medicine: No nutrient is more important for decreasing cardio-vascular death - and more lacking - than omega-3. US News and World Report, Aug. 7; http://health.usnews.com/articles/ health/heart/2008/08/07/from-fish-oil-tomedicine-print.htm.
25. http://efaeducation. nih.gov/sig/kim.html.
26. http://books.nap. edu/books/0309069351/html/21.htmlntroduction
27. Tribole, E. (2007). The ultimate omega-3 diet: Maximize the power of omega-3s to supercharge your health, battle inflammation, and keep your mind sharp. New York: McGraw Hill.
28. Quilici, S., Martin, M., McGuire, A. and Zoellner, Y. (2006). A cost-effectiveness analysis of n-3 PUFA (Omacor) treatment in post-Mi patients, Int J Clin Pract., Aug, 60 (8), 922-932.